Figure 1. (a) Dose distribution of dynamic conformal photon therapy

Slides:

Advertisements

Similar presentations

Advertisements

SNC2D. Primary LIGHT colours are red, green, and blue SECONDARY light colours are created by combining only two of the three primary colours of light.

Mrs. Smith’s 7th Grade Reading Blue Class Mrs. Smith’s 7th Grade Reading Blue Class Mrs. Smith’s 7th Grade Reading Blue Class.

Heavy Ion Tumor Therapy

Comparison of Rectal Dose Volume Histograms for Definitive Prostate Radiotherapy Among Stereotactic Radiotherapy, IMRT, and 3D-CRT Techniques Author(s):

Treatment Techniques for the Pelvis Region - Prostate - (- Cervix Ca -) Uwe Götz, Bernd Schicker Institute of Radiation Oncology Limburg, Germany Treatment.

H Ariyaratne1,2, H Chesham2, J Pettingell2, K Sikora2, R Alonzi1,2

The Color Wheel Claire Heider The Primary Colors.

Online Guidance of Tumor Targeted Prostate Brachytherapy using Histologically Referenced MRI C. Ménard 1, J. Lee 1, A. Rink 1, J. Abed 1, D. Iupati 1,

Cancer.orgPredict Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung.

Color Distribution A block BrownYellowOrangeRedGreenBlue GreenYellowOrangeRedPurple M&M Skittles.

Optimization of Volumetric Modulated Arc Therapy (VMAT) Planning Strategy Using Ring-shaped ROI for Localized Prostate cancer Kentaro Ishii, Masako Hosono,

Drought in the Western U.S.. Mean US Precipitation (in inches) Average Precipitation in 1 Year (in inches):

External Beam Radiotherapy for Differentiated Thyroid Cancer

Baseline Respiratory Parameters Documented

Table 1 Symptoms and signs at presentation

Figure 2. Kaplan–Meier survival analysis in patients

Evaluation Of RTOG Guidelines For Monte Carlo Based Lung SBRT Planning

Tumour-Targeted Treatment Intensification for Prostate Cancer Using Magnetic Resonance Imaging Guidance Jessy Abed, RTT, MHScMRS, Jenny Lee, MMath, Tim.

Figure 1. The (a) anterior–posterior and (b) right-lateral fields and (c, d) the isodose distributions of two axial planes in one patient with T2 stage.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Insert tables Insert graphs Insert figure

Figure 5 Schematic illustration of different clinical trial designs

Insert tables Insert graphs Insert figure

Average Number of Photons

European Urology Oncology

European Urology Oncology

Postoperative Proton Therapy in the Management of Stage III Thymoma

External Beam Radiotherapy as Curative Treatment of Prostate Cancer

Figure 5 The biological effects of charged particles

Figure 2 Nonmalignant tissue can be spared from radiation

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Dosimetric Benefits and Practical Pitfalls of Daily Online Adaptive MRI-Guided Stereotactic Radiation Therapy for Pancreatic Cancer Nancy El-Bared, MD,

Can I color yellow?. Can I color yellow?

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 1. Non-biochemical recurrence rate for the entire population (n = 122). From: Salvage radiation therapy for prostate cancer patients after prostatectomy.

Results of a Multicentric In Silico Clinical Trial (ROCOCO): Comparing Radiotherapy with Photons and Protons for Non-small Cell Lung Cancer Erik Roelofs,

Figure 1 Comparison of LDR‑BT, HDR‑BT, and EBRT

VMAT radiation-induced nausea and vomiting in adjuvant breast cancer radiotherapy: The incidental effect of low-dose bath exposure G. Lazzari, A. Terlizzi,

Half-Body Irradiation With Tomotherapy for Pain Palliation in Metastatic Breast Cancer Carlo Furlan, MD, Marco Trovo, MD, Annalisa Drigo, ScD, MPh, Elvira.

What Color is it?.

Figure 2 Variations between planned and delivered doses of radiation

Figure 2 The evolution of brachytherapy for prostate cancer

Simultaneous integrated prophylactic cranial irradiation in sino-nasal cancer Kenneth Jensen, Maja Bendtsen Sharma, Simon Lenler-Eriksen, Per Friis, Anne.

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Technical Advances of Radiation Therapy for Thymic Malignancies

Carbon Ion Radiotherapy for Stage I Non-small Cell Lung Cancer Using a Regimen of Four Fractions during 1 Week Tadaaki Miyamoto, MD, PhD, Masayuki Baba,

Innovations in the Radiotherapy of Non–Small Cell Lung Cancer

Technical Innovations and Patient Support in Radiation Oncology

Physics and Imaging in Radiation Oncology

Clinical and radiobiological evaluation of a method for planning target volume generation dependent on organ-at-risk exclusions in magnetic resonance.

Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy Robert Thompson, MD, Meredith Giuliani, MBBS, Mei Ling Yap,

Nicholas Trakul, MD, PhD, Jeremy P

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Whole-ventricular irradiation for intracranial germ cell tumors: Dosimetric comparison of pencil beam scanned protons, intensity-modulated radiotherapy.

Figure 3 Target volume definitions

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Guru Sonpavde, MD, Teresa G. Hayes, MD Mayo Clinic Proceedings

Colours Дополнительный иллюстративный материал

Technical Innovations and Patient Support in Radiation Oncology

Let’s Learn the Basic Colors

CORE: A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy (SBRT)) in Extracranial oligometastases (CRUK/14/038)

Clinical and Translational Radiation Oncology

Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal.

A, Top inhibitors of Ba/F3 transformed with CD74–ROS1, color coded by clinical development status: FDA-approved (green), phase III (yellow), phase II (blue),

Average Dose-Volume Ratio

Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal.

Survival, subsequent therapies, and response.

Volumetric and dosimetric comparison of two delineation guidelines for the radiation treatment of laryngeal squamous cell carcinoma C. Bondue, S. Racadot,

Presentation transcript:

Figure 1. (a) Dose distribution of dynamic conformal photon therapy Figure 1. (a) Dose distribution of dynamic conformal photon therapy. (b) Dose distribution of proton boost therapy. Lateral opposed portals using proton beam can provide good dose coverage to the prostate and reduce the unnecessary irradiated volume of both the ventral and dorsal portion of the body. Isodose lines: orange, 105%; magenta, 100%; yellow, 95%; light green, 90%; light blue, 80%; light purple, 50%; purple, 20%. Red line shows the planning target volume. From: Phase II Feasibility Study of High-Dose Radiotherapy for Prostate Cancer Using Proton Boost Therapy: First Clinical Trial of Proton Beam Therapy for Prostate Cancer in Japan Jpn J Clin Oncol. 2005;35(12):745-752. doi:10.1093/jjco/hyi193 Jpn J Clin Oncol | © 2005 Foundation for Promotion of Cancer Research

Figure 2. Image subtraction method for verification of patient positioning. From: Phase II Feasibility Study of High-Dose Radiotherapy for Prostate Cancer Using Proton Boost Therapy: First Clinical Trial of Proton Beam Therapy for Prostate Cancer in Japan Jpn J Clin Oncol. 2005;35(12):745-752. doi:10.1093/jjco/hyi193 Jpn J Clin Oncol | © 2005 Foundation for Promotion of Cancer Research

Figure 3. PSA-failure free survival for all patients. From: Phase II Feasibility Study of High-Dose Radiotherapy for Prostate Cancer Using Proton Boost Therapy: First Clinical Trial of Proton Beam Therapy for Prostate Cancer in Japan Jpn J Clin Oncol. 2005;35(12):745-752. doi:10.1093/jjco/hyi193 Jpn J Clin Oncol | © 2005 Foundation for Promotion of Cancer Research

Figure 4. Comparison of average rectal DVHs between photon/proton combined therapy and proton therapy alone. From: Phase II Feasibility Study of High-Dose Radiotherapy for Prostate Cancer Using Proton Boost Therapy: First Clinical Trial of Proton Beam Therapy for Prostate Cancer in Japan Jpn J Clin Oncol. 2005;35(12):745-752. doi:10.1093/jjco/hyi193 Jpn J Clin Oncol | © 2005 Foundation for Promotion of Cancer Research